Intraperitoneal insulin in uraemic diabetics undergoing continuous ambulatory peritoneal dialysis.

Oxidative stress evaluation in uraemic patients undergoing continuous ambulatory peritoneal dialysis

Since the great bulk of evidences regarding oxidative stress associated with chronic renal failure (CRF) came from haemodialysis patients and only scant data is available concerning peritoneal dialysis, we investigated the oxidative status in CRF patients on continuous ambulatory peritoneal dialysis (CAPD). Plasma lipid peroxidation assayed as thiobarbituric acid reactive substances (TBARS; nmo...

Intraperitoneal Versus Subcutaneous Insulin Treatment in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis Therapy

Nutrition in diabetic patients undergoing continuous ambulatory peritoneal dialysis.

I n the pre-dialysis stage, the nutritional management of diabetic patients with chronic renal fail ure involves mainly caloric and protein intake and control of blood sugar. These aspects are very important because severity of hyperglycemia is correlated with the rate of progression of chronic renal failure, while strict glycemic control can markedly diminish the likelihood of nephropathy and ...

Tuberculous peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis.

Complication of peritonitis developed in a 61 year old patient who was undergoing continuous ambulatory peritoneal dialysis (CAPD) and whose dialysate culture was negative for both aerobic and anaerobic bacteria and fungi. Despite the administration of various antibiotics and repeated mechanical lavages, inflammatory response and fever could not be controlled and therefore on the 8th hospital d...

Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis.

The pharmacokinetics of ceftizoxime were studied in 12 patients on continuous ambulatory peritoneal dialysis. After a 3-g intravenous dose, the steady-state volume of distribution was 0.23 +/- 0.05 liter kg-1, with an elimination half-life of 9.7 +/- 5.1 h. The peritoneal clearance of ceftizoxime (2.8 +/- 0.7 ml min-1) contributed modestly to the overall serum clearance of the drug (17.1 +/- 7....